http://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00English RSS Feedhttp://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pngEnglish RSS Feed2020-10-09 06:15:002020-10-09 06:15:00Novartis received European Medicines Agency (EMA) PRIME designation for iptacopan (LNP) in C3 glomerulopathy (C3G)